SEATTLE and VANCOUVER, BC, Sept. 3,
2020 /PRNewswire/ -- Achieve Life Sciences, Inc.
(Nasdaq: ACHV), a clinical-stage pharmaceutical company committed
to the global development and commercialization of cytisinicline
for smoking cessation, today announced that it will present at two
upcoming investor conferences.
- H.C. Wainwright 22nd Annual Global Investment Conference on
Wednesday, September
16th
-
- John Bencich, Chief Financial
and Operating Officer, will present a virtual corporate overview at
the H.C. Wainwright 22nd Annual Global Investment Conference on
Wednesday, September 16th
at 3:30 PM ET. A live webcast of the
presentation can be accessed by visiting
http://ir.achievelifesciences.com/events-and-webcasts. A replay of
the presentation will be archived on Achieve's website following
the conference.
- Lake Street Capital Markets 4th Annual Best Ideas
Growth (BIG4) Conference on Thursday,
September 17th
-
- Management will be hosting one-on-one meetings with investors
at the Lake Street Capital Markets 2020 Best Ideas Growth (BIG4)
Conference, to be held virtually on Thursday, September 17th, 2020. This
conference is an invitation-only event, featuring over 50 dynamic,
small-cap companies interacting with top institutional investors.
For those interested in arranging a one-on-one meeting with Achieve
management, please contact your Lake Street Capital Markets
representative.
About Achieve and Cytisinicline
Tobacco use is
currently the leading cause of preventable death and is responsible
for more than eight million deaths annually worldwide.1
It is estimated that 28.7% of cancer deaths in the U.S. are
attributable to cigarette smoking.2 Achieve's focus is
to address the global smoking health and nicotine addiction
epidemic through the development and commercialization of
cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it
is estimated that over 20 million people have used cytisinicline to
help combat nicotine addiction.
Investor Relations Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
1 World Health Organization. WHO Report on the
Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017
2 Annals of Epidemiology, Volume 25, Issue 3, 179 -
182.e1
View original content to download
multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-to-present-at-upcoming-investor-conferences-301123636.html
SOURCE Achieve Life Sciences, Inc.